Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK Clarifies RWD Collection Rules Under Early Access Scheme

Executive Summary

New UK guidance says companies do not have to apply for clinical trial approval or ethics review to collect data on the clinical management of patients receiving unapproved drugs under an early access scheme. However, consent is needed where such data may have research value once collected.

You may also be interested in...



UK’s Early Access To Medicines Scheme To Get New Legal Basis

Legal clarity around the core principles of the UK’s early patient access scheme is expected to benefit the pharma industry, patients and healthcare professionals.

EMA Gives Advice On Biomarker That Could Speed Up AML Drug Development

The European Medicines Agency has issued a “letter of support” to encourage ongoing efforts by an industry-led consortium to establish measurable residual disease as a surrogate efficacy endpoint in clinical studies of patients with acute myeloid leukemia. 

EMA Seeks To Update & Improve Guidance On Non-Inferiority Trials

The European Medicines Agency expects its new guideline will improve planning of confirmatory trials that include non-inferiority and therapeutic equivalence comparisons.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS146103

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel